Search Result

Results for "

Coronary heart disease.

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (3) Akt (1) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (4) Autophagy (1) Calcium Channel (2) CETP (1) Endogenous Metabolite (3) HIF/HIF Prolyl-Hydroxylase (1) Interleukin Related (1) Isotope-Labeled Compounds (1) NF-κB (1) P-glycoprotein (1) PI3K (1) Potassium Channel (1) Protease Activated Receptor (PAR) (1) Ser/Thr Protease (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (20) Endocrinology (3) Inflammation/Immunology (1) Metabolic Disease (5) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P4153

Enlicitide chloride MK-0616 chloride	Ser/Thr Protease	Cardiovascular Disease
Enlicitide chloride is a potent PCSK9 antagonist. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders[1] .

HY-N0852

Benzoylpaeoniflorin	Apoptosis	Cardiovascular Disease
Benzoylpaeoniflorin, a natural product from Chinese paeony root, has the potential for coronary heart disease by decreasing apoptosis.

HY-B0203

Nebivolol 3 Publications Verification R 065824	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Nebivolol (R 065824) is an orally active beta receptor blocker and has the high beta(1)-receptor affinity. Nebivolol has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .

HY-B0203A

Nebivolol hydrochloride 3 Publications Verification R 065824 hydrochloride	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Nebivolol (R 065824) hydrochloride is an orally active beta receptor blocker and has the high beta(1)-receptor affinity.Nebivolol hydrochloride has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .

HY-W004284S

Heptadecanoic acid-d3	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease Cancer
Heptadecanoic acid-d₃ is the deuterium labeled Heptadecanoic acid. Heptadecanoic acid is an odd chain saturated fatty acid (OCS-FA). Heptadecanoic acid is associated with several diseases, including the incidence of coronary heart disease, prediabetes and type 2 diabetes as well as multiple sclerosis[1].

HY-W004284S1

Heptadecanoic acid-d33	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease Cancer
Heptadecanoic acid-d₃₃ is the deuterium labeled Heptadecanoic acid. Heptadecanoic acid is an odd chain saturated fatty acid (OCS-FA). Heptadecanoic acid is associated with several diseases, including the incidence of coronary heart disease, prediabetes and type 2 diabetes as well as multiple sclerosis[1].

HY-N1179

Tanshinone IIB	Apoptosis	Cardiovascular Disease Neurological Disease
Tanshinone IIB is a major active constituent of the roots of Salvia miltiorrhiza (Danshen) widely used for the research of stroke and coronary heart disease in Asian countries. Tanshinone IIB has a neuroprotective effect via inhibition of apoptosis .

HY-N8598

Caulophine	Others	Cardiovascular Disease
Caulophine is a fluoroketone alkaloid isolated from Caulophyllum robustum MAXIM. Caulophine has antioxidant activity and the ability to protect cardiomyocytes from oxidative and ischemic damage, providing potential value for coronary heart disease research .

HY-P1536

Thrombin Receptor Activator for Peptide 5 (TRAP-5)	Protease Activated Receptor (PAR)	Cardiovascular Disease
Thrombin Receptor Activator for Peptide 5 (TRAP-5) is also called Coagulation Factor II Receptor (1-5) or Proteinase Activated Receptor 1 (1-5), used in the research of coronary heart disease (CHD).

HY-B0203AR

Nebivolol (hydrochloride) (Standard) R 065824 hydrochloride (Standard)	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Nebivolol (hydrochloride) (Standard) is the analytical standard of Nebivolol (hydrochloride). This product is intended for research and analytical applications. Nebivolol (R 065824) hydrochloride is an orally active beta receptor blocker and has the high beta(1)-receptor affinity.Nebivolol hydrochloride has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .

HY-W004284

Heptadecanoic acid 2 Publications Verification	Apoptosis PI3K Akt	Cardiovascular Disease Metabolic Disease Cancer
Heptadecanoic acid is an odd-chain saturated fatty acid (OCS-FA) with oral activity. Heptadecanoic acid can inhibit cell proliferation and induce Apoptosis. Heptadecanoic acid has antitumor activity. Heptadecanoic acid is associated with a number of diseases, including coronary heart disease, pre-diabetes and type 2 diabetes, and multiple sclerosis .

HY-107197

8-Prenylchrysin	P-glycoprotein	Cancer
8-prenylchrysin is a C8-prenylated flavonoid. 8-prenylchrysin inhibits P-gp. 8-prenylchrysin can be used for tumor research .

HY-B0130S

Perindopril-d4 erbumine	Isotope-Labeled Compounds Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease Cancer
Perindopril-d4 t-butylamine salt is the deuterium labeled Perindopril t-butylamine salt. Perindopril t-butylamine salt is a long-acting ACE inhibitor of which is used to treat high blood pressure, heart failure or stable coronary artery disease .

HY-B0642

Isosorbide mononitrate 4 Publications Verification Isosorbide-5-mononitrate	Autophagy Endogenous Metabolite Apoptosis	Cardiovascular Disease Cancer
Isosorbide mononitrate (Isosorbide-5-mononitrate) is an orally active nitric acid compound used for angina pectoris by dilating blood vessels and lowering blood pressure. Isosorbide mononitrate increases the viability and proliferation of HUVECs by decreasing Apoptosis and elevated the expressions of vedf, kdrl, pdgfr in zebrafish embryos. Isosorbide mononitrate is promising for research of heart failure and coronary heart disease .

HY-132303

MK-8262	CETP	Cardiovascular Disease Metabolic Disease
MK-8262 is an orally active and potent cholesteryl ester transfer protein (CETP) inhibitor with an IC₅₀ of 53 nM and a log D of 5.3. MK-8262, a bistrifluoromethyl analogue, has the potential for coronary heart disease (CHD) correlated high-density lipoprotein (HDL) and low-density lipoprotein (LDL) research .

HY-100418

SKA-111	Potassium Channel	Cardiovascular Disease
SKA-111 is a selective activator of potassium phannel K_Ca3.1 , evokes K_Ca3.1 membrane hyperpolarization in porcine endothelial cell. SKA-111 is capable of improving Bradykinin (HY-P0206)-induced coronary dilations in the isolated rat heart and can be used for cardiovascular disease research .

HY-167712

(2R,3S)-Azelaprag (2R,3S)-AMG 986	Others	Cardiovascular Disease Metabolic Disease
(2R,3S)-Azelaprag ((2R,3S)-AMG 986) is an Apelin receptor agonist with an EC50 of 0.012 µM for Apelin receptors, and it is utilized in the treatment of various conditions such as heart failure, atherosclerosis, obesity, diabetes mellitus, amyotrophic lateral sclerosis, coronary artery disease, hypertension, stroke, and myocardial infarction.

HY-N4192

Toringin	Others	Cardiovascular Disease Cancer
Toringin, a bioflavonoid, is isolated from the bark of Docyniopsis tschonoski. Toringin progressively decreases not only the cis-effect of the expanded CTG repeats but cytotoxicity as well. Exposure to isosakuranetin, Toringin rescues PC12 neuronal cells. Flavonoids are efficacious for ameliorating the RNA gain of function caused by expanded CTG repeats, and have various biological activities and beneficial actions against cancers, coronary heart disease, among other pathologies .

HY-44809A

Izilendustat hydrochloride	HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology Cancer
Izilendustat (hydrochloride) is a potent inhibitor of prolyl hydroxylase which stabilizes hypoxia inducible factor- 1 alpha (HIF- lα), as well as hypoxia inducible factor-2 (HIF-2). Izilendustat (hydrochloride) has the potential for the research of HIF- lα related diseases including Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, anemia, colitis, and other inflammatory bowel diseases (extracted from patent WO2011057115A1/WO2011057112A1/WO2011057121A1) .

HY-107802

Breviscapine Breviscapinun	NF-κB Interleukin Related	Cardiovascular Disease
Breviscapine is a crude flavonoid extract of Breviscapine, which is more than 85% of the active ingredient, Breviscapine. Breviscapine has a wide range of cardiovascular pharmacological activities, such as increasing blood flow, improving microcirculation, dilating blood vessels, reducing blood viscosity, promoting fibrinolysis, inhibiting platelet aggregation and thrombosis. Breviscapine has been used in the study of cerebral infarction and its sequelae, cerebral thrombosis, coronary heart disease and angina pectoris .

HY-101390

(+)-Niguldipine hydrochloride (S)-Niguldipine hydrochloride	Calcium Channel	Cardiovascular Disease
(+)-Niguldipine hydrochloride is an antagonist for calcium channel. (+)-Niguldipine hydrochloride produces vasodilation by blocking calcium channels and reducing the transmembrane influx of calcium ions. (+)-Niguldipine hydrochloride inhibits U-46619 (HY-108566)-induced coronary vasoconstriction in guinea pig Langendorff heart with pID₅₀ of 11.37, binds to calcium channel on guinea pig skeletal muscle membrane with K_i of 9.75, and lowers the blood pressure in spontaneously hypertensive rat with pED₃₀ of 7.1. (+)-Niguldipine hydrochloride ameliorates cardiovascular diseases such as hypertension, angina pectoris and arrhythmias .

HY-101390A

(-)-Niguldipine hydrochloride (R)-Niguldipine hydrochloride	Calcium Channel	Cardiovascular Disease
(-)-Niguldipine ((R)-Niguldipine) hydrochloride is a calcium channel antagonist. (-)-Niguldipine hydrochloride exerts a vasodilatory effect by blocking calcium channels and reducing the transmembrane influx of calcium ions. (-)-Niguldipine can inhibit U-46619 (HY-108566)-induced coronary artery contraction in guinea pig Langendorff hearts (pID₅₀ of 9.93), has high affinity for calcium channel binding sites on guinea pig skeletal muscle membranes (K_i of 8.10), and lowers blood pressure in spontaneously hypertensive rats (pED₃₀ of 5.55). (-)-Niguldipine hydrochloride can improve cardiovascular diseases such as hypertension, angina pectoris, and arrhythmias .

Cat. No.	Product Name

HY-L046

Anti-Cardiovascular Disease Compound Library	1,758 compounds
Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels which include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, etc. CVDs are the number 1 cause of death globally. Smoking, unhealthy nutrition, aging population, lack of physical activity, arterial hypertension, or diabetes can promote cardiovascular disease like myocardial infarction or stroke. It is multifactorial and encompasses a multitude of mechanisms, such as eNOS uncoupling, reactive oxygen species formation, chronic inflammatory disorders and abnormal calcium homeostasis. Antioxidant, anti-inflammatory and anti-diabetes agents may reduce the cardiovascular disease risk. MCE supplies a unique collection of 1,758 compounds with confirmed anti-cardiovascular activity. These compounds mainly target metabolic enzyme, membrane transporter, ion channel, inflammation related signaling pathways. MCE Anti-Cardiovascular Disease Compound Library can be used for cardiovascular diseases related research and high throughput and high content screening for new drugs.

Anti-Cardiovascular Disease Compound Library

1,758 compounds

Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels which include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, etc. CVDs are the number 1 cause of death globally. Smoking, unhealthy nutrition, aging population, lack of physical activity, arterial hypertension, or diabetes can promote cardiovascular disease like myocardial infarction or stroke. It is multifactorial and encompasses a multitude of mechanisms, such as eNOS uncoupling, reactive oxygen species formation, chronic inflammatory disorders and abnormal calcium homeostasis. Antioxidant, anti-inflammatory and anti-diabetes agents may reduce the cardiovascular disease risk.

MCE supplies a unique collection of 1,758 compounds with confirmed anti-cardiovascular activity. These compounds mainly target metabolic enzyme, membrane transporter, ion channel, inflammation related signaling pathways. MCE Anti-Cardiovascular Disease Compound Library can be used for cardiovascular diseases related research and high throughput and high content screening for new drugs.

HY-L087

Anti-Obesity Compound Library	2,618 compounds
Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries. MCE Anti-Obesity Compound Library owns a unique collection of 2,618 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Anti-Obesity Compound Library

2,618 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 2,618 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Cat. No.	Product Name	Target	Research Area